

Accepted Manuscript

Pharmacodynamic and pharmacokinetic characteristics of YMR-65, a tubulin inhibitor, in tumor-bearing mice

Ali Fan, Jiali Wei, Mengru Yang, Qing Zhang, Yaliang Zhang, Qingwang Liu, Ning Li, Di Zhao, Yang Lu, Junxiu Li, Jie Zhao, Shuhua Deng, Bingjie Zhang, Hailiang Zhu, Xijing Chen



PII: S0928-0987(18)30230-6
DOI: doi:[10.1016/j.ejps.2018.05.011](https://doi.org/10.1016/j.ejps.2018.05.011)
Reference: PHASCI 4522

To appear in: *European Journal of Pharmaceutical Sciences*

Received date: 27 January 2018
Revised date: 8 May 2018
Accepted date: 14 May 2018

Please cite this article as: Ali Fan, Jiali Wei, Mengru Yang, Qing Zhang, Yaliang Zhang, Qingwang Liu, Ning Li, Di Zhao, Yang Lu, Junxiu Li, Jie Zhao, Shuhua Deng, Bingjie Zhang, Hailiang Zhu, Xijing Chen , Pharmacodynamic and pharmacokinetic characteristics of YMR-65, a tubulin inhibitor, in tumor-bearing mice. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Phasci(2017), doi:[10.1016/j.ejps.2018.05.011](https://doi.org/10.1016/j.ejps.2018.05.011)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Pharmacodynamic and pharmacokinetic characteristics of YMR-65, a tubulin inhibitor, in tumor-bearing mice

Ali Fan¹, Jiali Wei¹, Mengru Yang², Qing Zhang¹, Yaliang Zhang², Qingwang Liu³, Ning Li¹, Di Zhao¹, Yang Lu¹, Junxiu Li⁴, Jie Zhao¹, Shuhua Deng⁵, Bingjie Zhang¹, Hailiang Zhu^{2*} & Xijing Chen^{1*}

Affiliation:

1. Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198 (P.R. China)

2. State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, 210023 (PR. China)

3. Institute of Technology Innovation, HeFei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031 (P.R. China)

4. Jiangsu Hengrui Medicine CO.LTD, Lianyungang, Jiangsu Province, 222047 (P.R. China)

5. Guangzhou Huiai Hospital (The Affiliated Brain Hospital of Guangzhou Medical University) Guangzhou, China, 510370 (P.R. China)

* The two authors were considered as co-corresponding authors:

Prof. Dr. Hailiang Zhu and Dr. Xijing Chen

Tel.: +86 25 8618 5379; Fax: +86 25 8618 5379

E-mail addresses: zhuhl@nju.edu.cn (Hailiang Zhu); chenxj-lab@hotmail.com (Xijing Chen)

Full postal address: Clinical Pharmacokinetics Laboratory, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, #639 Longmian Avenue, Jiangning District, Nanjing, 211198, China.

Download English Version:

<https://daneshyari.com/en/article/8510893>

Download Persian Version:

<https://daneshyari.com/article/8510893>

[Daneshyari.com](https://daneshyari.com)